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Abstract
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Ser ial  accumulat ion of  mut at ions t o f ixat ion in t he SLYNTVATL (SL9) immunodominant ,  HIV p17 Gag-der ived,  HLA A2-rest r ict ed CTL
epi t ope produce t he SLFNTIAVL t r iple mut ant  ‘ ul t imat e’  escape var iant .  These mut at ions in solvent -exposed residues are bel ieved
t o int er f ere wi t h TCR recogni t ion,  al t hough conf i rmat ion has awai t ed st ruct ural  ver i f i cat ion.  Here,  we solved a TCR co-complex
st ruct ure wi t h SL9 and t he t r iple escape mut ant  t o det ermine t he mechanism of  immune escape in t his eminent  syst em.  We show
t hat ,  in cont rast  t o prevai l ing hypot heses,  t he main TCR cont act  residue is 4N and t he dominant  mechanism of  escape is not  via
lack of  TCR engagement .  Inst ead,  mut at ion of  solvent  exposed residues in t he pept ide dest abi l ize t he pept ide-HLA and reduce
pept ide densi t y at  t he cel l  sur f ace.  These resul t s highl ight  t he ext raordinary lengt hs t hat  HIV employs t o evade det ect ion by
high-af f ini t y TCRs wi t h a broad pept ide-binding f oot pr int  and necessi t at e reevaluat ion of  t his exemplar  model  of  HIV TCR escape.
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 21 
ABSTRACT 22 
Serial accumulation of mutations to fixation in the SLYNTVATL (SL9) immunodominant, HIV p17 23 
Gag-derived, HLA A2-restricted CTL epitope produce the SLFNTIAVL triple mutant ‘ultimate’ 24 
escape variant. These mutations in solvent-exposed residues are believed to interfere with TCR 25 
recognition, although confirmation has awaited structural verification. Here, we solved a TCR co-26 
complex structure with SL9 and the triple escape mutant to determine the mechanism of immune 27 
escape in this eminent system. We show that, in contrast to prevailing hypotheses, the main TCR 28 
contact residue is 4N and the dominant mechanism of escape is not via lack of TCR engagement. 29 
Instead, mutation of solvent exposed residues in the peptide destabilize the peptide-HLA and reduce 30 
peptide density at the cell surface. These results highlight the extraordinary lengths that HIV employs 31 
to evade detection by high-affinity TCRs with a broad peptide-binding footprint and necessitate 32 
reevaluation of this exemplar model of HIV TCR escape.  33 
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1. INTRODUCTION 37 
CD8+ cytotoxic T lymphocytes (CTLs) form a critical component in immune control of HIV 38 
infection. However, the virus has adopted numerous strategies to evade detection by these important 39 
immune cells (1, 2). Notably, the high rate and poor fidelity of replication produces a viral 40 
quasispecies to allow rapid selection of sequence variants that evade CTLs. This immune escape 41 
mutation is often associated with loss of viral fitness (3). The effects of immune escape from some 42 
HLA class I alleles, particularly HLAs B27 and B57 (3, 4), can be significant and delay progression 43 
to AIDS. There has been considerable work on immune escape from HIV epitopes presented by the 44 
most frequent HLA worldwide, HLA A2 (5). The majority of these studies have focused on the 45 
immunodominant response through the p17 HIV Gag-derived epitope SL9 (amino acids 77–85, 46 
sequence SLYNTVATL) (6-23). Responses to SL9 are uncommon in acute infection but are 47 
dominant during the long, asymptomatic, chronic infection period where over 70% of HLA A2+ HIV 48 
infected individuals mount a strong response to this epitope (13, 18, 19). Immune escape from SL9-49 
specific CTL during this period has been studied extensively and is known to follow well-described 50 
patterns (6, 7). The leucine residues at positions 2 and 9 in SL9, are located within an a helix (21) 51 
and are critical for trimerization of the P17 Gag protein (24). Mutations within these residues are 52 
believed to produce highly compromised virus (11, 24). These residues also act as the principal 53 
anchors for securing SL9 into the HLA A2 binding groove (22) and ensure that the virus does not use 54 
the archetypical escape strategy of mutating primary MHC anchors to block epitope presentation at 55 
the infected cell surface (25-27). Instead, in the face of SL9-specific CTL pressure, HIV has been 56 
observed to undergo preferred mutation at positions 3, 6 and 8 in the epitope (6, 7, 9). The dominant 57 
mutations seen at these positions (Y3F, V6I and T8V) correlate with a lower viral load suggesting 58 
that they result in a loss of viral fitness, a notion that is supported by the rapid reversion to the 59 
wildtype SL9 sequence in the absence of T-cell selection pressure (6, 7). The available evidence 60 
suggests that HIV balances the combined pressures of immune escape versus viral fitness at the SL9 61 
epitope by successive fixation of mutations at positions 3, 6 and 8 in the subtype A, B and D SL9 62 
SLYNTVATL consensus sequence over a >10-year period (6, 7). Indeed, McMichael and colleagues 63 
have described the triple mutant SLFNTIAVL sequence (3F6I8V; mutations in bold underlined text) 64 
as the ‘ultimate’ escape mutant in SL9 (6). 65 
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Here we use structure and protein biophysics to deconstruct how HIV escapes from the well-studied 66 
(9-11) SL9-specific 868 TCR. We add to the existing data by providing the first ever TCR-pMHC 67 
structures in this exemplar model of how HIV evades engagement by host TCRs. We find that the 68 
868 TCR interacts with HLA A2-SLYNTVATL (A2-peptide from here on in) with the expected 69 
binding topography but exhibits an unusual degree of structural rearrangement upon interaction with 70 
A2-SLYNTVATL. The 868 TCR also contacts all five central residues in SL9 (position 3-8) and 71 
binds with an unprecedentedly high affinity for a natural TCR. Surprisingly, 4N is the major contact 72 
residue – not the 3Y, 6I or 8T that mutate to precipitate immune escape. This enabled the generation 73 
of a high-resolution structure of the 868 TCR in complex with the SLFNTIAVL ultimate escape 74 
variant. These results challenge current thinking on the mechanism by which HIV escapes at SL9 and 75 
demonstrate the extraordinary tactics that the virus can employ to escape from CTL responses that 76 
can involve TCRs with a very broad footprint and a very high natural binding affinity.  77 
2. MATERIALS AND METHODS 78 
2.1 Construct design 79 
The 868 TCR α and β chains, HLA A2 heavy chain and β2m chain were generated by PCR 80 
mutagenesis and cloning. All sequences were confirmed by automated DNA sequencing (Lark 81 
Technologies). TCR expression constructs were designed with a disulphide linked construct to 82 
produce the soluble domains (variable and constant) for both the α (residues 1-207) and β chains 83 
(residues 1 – 247) (44, 45). The HLA A2 heavy chain (residues 1-248) (α1, α2 and α3 domains), 84 
tagged, or not tagged with a biotinylation sequence, and β2m (residues 1 – 100) were also cloned and 85 
used to make the pMHCI complexes. The TCR α and β chains, the HLA A2 α chain and β2m 86 
sequences were inserted into separate pGMT7 expression plasmids under the control of the T7 87 
promoter (46). 88 
2.2 Protein expression, refolding and purification 89 
Competent Rosetta DE3 E.coli cells were used to produce the TCR α and β chains, HLA A2 heavy 90 
chain and β2m in the form of inclusion bodies (IBs) using 0.5 mM IPTG to induce expression and 91 
protein were chemically refolded as described previously (47).  92 
2.2.1 pMHCI biotinylation 93 
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Biotinylated pMHCI was prepared as previously described (48).  95 
2.3 SPR experiments 96 
SPR equilibrium binding analysis was performed using a BIAcore T100TM equipped with a CM5 97 
sensor chip as previously reported (48, 49). HLA DR1, generated as in (50), was used as a negative 98 
control on flow cell 1. SPR kinetic analyses were carried out to determine the KD values for the TCR, 99 
at 25°C. For all kinetic experiments, approximately 300 RUs of pMHC was coupled to the CM5 100 
sensor chip surface. The TCR was then injected at concentrations ranging from 10 times above and 101 
10 times below the known KD of the interaction at 45 µl / min. The KD values were calculated 102 
assuming 1 : 1 Langmuir binding (AB = B*ABMAX/(KD + B)) and the data were analyzed using a 103 
global fit algorithm (BIAevaluationTM 3.1). The kon, koff and KD values were calculated by global 104 
fitting of the data using BIAevaluationTM 3.1 software. For the thermodynamics experiments we used 105 
the KD determined by SPR at different temperatures with the standard thermodynamic equation ΔG = 106 
RT ln KD and the standard non-linear van’t Hoff equation (ΔG° = ΔH° –TΔS° + ΔCp°(T-T0) – 107 
TΔCp° ln (T/T0)) with T0=298 K. For stability experiments, single injections of 50 µM 868 TCR over 108 
the SL9 variants were performed after different incubation times at 37°C, and the RU values were 109 
recorded. 110 
2.4 Isothermal Titration Calorimetry (ITC)  111 
ITC experiments were performed using a Microcal VP-ITC (GE Healthcare) as previously described 112 
(29), with 30 µM pHLA-I in the calorimeter cell and 210 µM soluble 868 TCR in the syringe. Buffer 113 
conditions were 20 mM Hepes (pH 7.4) containing 150 mM NaCl and 20 injections of 2µl volume 114 
each were performed. Results were processed and integrated with the Origin 6.0™ software 115 
distributed with the instrument. ITC experiments were performed in duplicate. 116 
2.5 Adhesion frequency assay  117 
We used an adhesion frequency assay to measure the 2D affinity of TCR–pMHC interactions at the 118 
cell membrane as previously described (51). Briefly, human T-cells transfected with the 868 TCR 119 
were mounted onto one micro-pipette and, on the other pipette, human red blood cells coated with 120 
pMHC by biotin–streptavidin coupling served as both a surrogate APC and an adhesion sensor for 121 
detecting the TCR–pMHC interaction. Site densities of TCR and pMHC were measured by flow 122 
cytometry as previously described (52). All assays were performed using at least 5 cell pairs, and 123 
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calculated as an average of 100 cell-cell contacts. 125 
2.6 Crystallization, diffraction data collection and model refinement 126 
All protein crystals were grown at 18 °C by vapour diffusion via the sitting drop technique. 200 nL of 127 
1:1 molar ratio TCR and pMHCI (10 mg/ml) in crystallization buffer (10 mM TRIS pH 8.1 and 10 128 
mM NaCl) was added to 200 nL of reservoir solution. 868 crystals were grown in TOPS (53) in 0.1 129 
M sodium cacodylate pH 6.5, 20% PEG 8000 and 0.2 M ammonium sulphate (53). 868-A2-130 
SLYNTVATL crystals were grown in TOPS in 0.1 M sodium cacodylate pH 6.0, 15% PEG 4000 and 131 
0.2 M ammonium sulphate (53). 868-A2-SLYNTIATL co-crystals were grown in TOPS in 0.1 M 132 
sodium cacodylate pH 6.0, 15% PEG 4000 and 0.2 M ammonium sulphate (53). 868-A2-133 
SLFNTIAVL crystals were grown in TOPS1 in 0.1 M sodium cacodylate pH 5.5, 15% PEG 4000 134 
and 0.2 M ammonium sulphate (53). A2-SLYNTIATL crystals were grown in TOPS in 0.1 M 135 
sodium cacodylate pH 6.0, 25% PEG 4000 and 0.2 M ammonium sulphate (53). A2-SLFNTIAVL 136 
crystals were grown in TOPS in 0.1 M sodium cacodylate pH 6.0, 25% PEG 4000 and 0.2 M 137 
ammonium sulphate (53). All crystals were soaked in 30% ethylene glycol before cryo-cooling. All 138 
crystallization screens and optimization experiments were completed using an Art-Robbins Phoenix 139 
dispensing robot (Alpha Biotech Ltd, UK). Data were collected at 100 K at the Diamond Light 140 
Source (DLS), Oxfordshire. All datasets were collected at a wavelength of ~0.98Å using an ADSC 141 
Q315 CCD or PILATUS Pixel detectors. Reflection intensities were estimated with the XIA2 142 
package (54) and the data were scaled, reduced and analyzed with SCALA and the CCP4 package 143 
(55). Structures were solved with molecular replacement using PHASER (56). Sequences were 144 
adjusted with COOT (57) and the models refined with REFMAC5. Graphical representations were 145 
prepared with PYMOL (58). The reflection data and final model coordinates were deposited with the 146 
PDB database (868, PDB: 5NMD; 868-A2-SLYNTVATL, PDB: 5NME; 868-A2-SLYNTIATL, 147 
PDB: 5NMF; 868-A2-SLFNTIAVL, PDB: 5NMG; A2-SLYNTIATL, PDB: 5NMH; A2-148 
SLFNTIAVL, PDB: 5NMK). 149 
2.7 Thermal stability CD analysis of HLA A2 complexes 150 
Thermal stability of HLA A2/β2m/peptide complexes was determined by circular dichroism 151 
spectroscopy following the change of ellipticities Θ at 218 nm using an Aviv 215 instrument (Aviv 152 
Biomedical Inc., Lakewood, NJ). Proteins were dissolved in 137 mM NaCl, 3 mM KCl, 8 mM 153 
Na2HPO4, 1 mM KH2PO4, pH 7.4, at concentrations of ~3 µM as determined spectroscopically using 154 
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calculated extinction coefficients (59). Melting curves were recorded from 4 °C up to a maximum 155 
temperature when protein aggregation was observed using a heating rate of ~0.5 °C/min. Melting 156 
curves were analysed assuming a two-state trimer-to-monomer transition from the native (N) to 157 
unfolded (U) conformation N3 ↔ 3U with an equilibrium constant K = [U]
3/[N3] = F/[3c
2 (1-F)3] 158 
where F and c are the degree of folding and protein concentration, respectively. Data were fitted as 159 
described (60) using the non-linear least-squares routine of Origin V7.5 (OriginLab, Northampton, 160 
MA). Fitted parameters were the melting temperature Tm, van't Hoff's enthalpy ΔHvH at the 161 
transition midpoint, and the slope and intercept of the native baseline assumed as a linear function of 162 
the temperature. As protein complexes aggregated at various degrees of unfolding, the ellipticity of 163 
the unfolded state was set as a constant of -4,500 deg cm2 dmol-1 (61). 164 
2.8 Generation of 868 TCR transgenic T-cells 165 
868 TCR construct (codon-optimized for human expression) was cloned into the third-generation 166 
lentiviral expression vector pELNS (kindly provided by James R. Riley, University of Pennsylvania, 167 
PA, USA). pELNS vector was engineered to contain rat CD2 (rCD2) gene to be used as a marker of 168 
lentiviral transduction of target cells. 868 TCR-α and TCR-β, and rCD2 were separated by a pair of 169 
‘self-cleaving’ 2A sequence (11). Lentiviral particles were prepared by calcium phosphate 170 
transfection of packaging plasmids (pRSV-Rev, pMDLg/pRRE, pMD2.G) together with 868-171 
encoding pELNS into HEK293T cells. Supernatant was harvested 48- and 72h post transfection, and 172 
was subsequently concentrated by ultracentrifugation. Primary CD8+ T-cells were obtained from 173 
healthy donor blood bags (Welsh Blood Service) by density gradient centrifugation and positive 174 
selection using CD8 MicroBeads (Miltenyi Biotec, Bergisch Gladbach, Germany). Isolated T-cells 175 
were stimulated overnight with Gibco human T-activator CD3/CD28 Dynabeads (ThermoFisher 176 
Scientific, Waltham, MA) at 3:1 bead to T-cell ratio, and transduced with concentrated lentiviral 177 
stock in presence of 5 µg/ml polybrene (Santa Cruz Biotechnology, Santa Cruz, CA). After 72 h 178 
rCD2+ cells were enriched by magnetic bead selection to yield >95% purity. For tetramer staining 179 
experiments CD8+ T-cells were used without magnetic enrichment to leave a non-transduced internal 180 
control cell population. Similar methodology was used to transduce TCRβ chain negative Jurkat cells 181 
to allow the examination of tetramer binding in the absence of the CD8 glycoprotein. 182 
2.9 Tissue culture 183 
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T2 cells were maintained as suspension cells in R10 (RPMI 1640 media, 10% FBS, penicillin, 184 
streptomycin and L-Glutamine, all Life Technologies, Paisley, UK) and passaged weekly or when 185 
required. Post enrichment, primary CD8+ T-cells were routinely expanded with allogeneic feeder 186 
PBMCs and phytohaemagluttinin (PHA) in T-cell media as previously described (40). 868 TCR 187 
expression was checked prior to assay using anti-rCD2 antibody and SLYNTVATL tetramer, with 188 
the protein kinase inhibitor Dasatinib (62) (Axon Medchem, Reston, VA), and unconjugated anti-PE 189 
antibody (PE001, BioLegend, London, UK) used to enhance tetramer staining, as previously 190 
described (40, 63). 191 
2.10 T-cell activation assays 192 
For peptide pulsing assays, T2 cells were incubated with peptide for 1h in 0.5 ml of AIM-V serum 193 
free media (ThermoFisher Scientific) in 5 ml FACS tubes at 37°C and 5% CO2, followed by 4 194 
washes with 4 ml of RPMI 1604 media. In assays using primary CD4+ T-cells as targets, these cells 195 
were purified from PBMC using magnetic microbead separation (Miltenyi Biotech). Peptides were 196 
synthesizsed to >95% purity, stored as 20 mM DMSO stocks at -80 °C and 1 mM RPMI dilutions 197 
made on the day of assay. DMSO controls were treated the same as peptide pulsed. Post pulsing, T2s 198 
or CD4+ T-cells were incubated in 4.5 ml of AIM-V media at 37°C and 5% CO2 for 3-24h or used 199 
immediately (0 h), such that cells were ready at the same time. 868 TCR transduced and non-200 
transduced T-cells (30,000) were rested overnight in R5 (as for R10 but with 5% fetal bovine serum) 201 
then co-incubated in 96U well plates with T2 or CD4+ T-cellss (60,000) in the presence of GolgiStop 202 
and GolgiPlug according the manufacturers (BD Biosciences, Oxford, UK), and anti-CD107a PE 203 
Antibody (H483, BD Biosciences). Controls included T-cells alone and T-cells with unpulsed T2s 204 
(negative control) or PHA. After 3.5-5h of incubation cells were labelled with the violet 205 
LIVE/DEAD fixable dead cell stain Vivid, anti-CD8 APC (BW135/80; Miltenyi Biotech) and anti-206 
CD19 pacific-blue (T2s) (BioLegend), rCD2 (CD4 assay) and anti-CD4 APC-Vio770 (M-T466, 207 
Miltenyi Biotech; CD4 assay) antibodies. Cells were then stained with anti-TNFα PE-Vio770 208 
antibody (CA2, Miltenyi Biotec) using a Cytofix/Cytoperm kit (BD Biosciences) according to 209 
manufacturer’s instructions. Flow cytometry was preformed on a FACSCanto II (BD Biosciences) 210 
and data analysed with FlowJo software (TreeStar, Ashland, OR). For peptide alanine scans 868 TCR 211 
transduced T-cells were rested overnight in R5 then incubated with T2s (60,000) and peptides at 212 
specified concentrations for 18h in 96U well plates in 100 μl of R5. Supernatants (50 μl) were used 213 
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for MIP-1β ELISA (R&D Systems, Minneapolis, Canada) and GraphPad Prism (GraphPad Software, 220 
Inc., La Jolla, CA) used to fit nonlinear regression curves and calculate EC50 for each peptide. 221 
2.11 T2 peptide HLA-A2 stability assays 222 
For conventional peptide binding assays, T2s were pulsed for 22h with 10-5 M peptide in 0.2 ml of 223 
AIM-V media (ThermoFisher Scientific) in 5ml FACS tubes at 37°C and 5% CO2, washed then 224 
stained with anti-HLA-A2 antibody (BB7.2 BioRad, Hercules, CA) for 10 minutes at RT, washed 225 
with PBS and fixed with 2% paraformaldehyde for 20 min on ice. Peptides were synthesised to >95% 226 
purity, stored as 20 mM DMSO stocks at -80 °C and 1 mM AIM-V dilutions made on the day of 227 
assay. DMSO controls were treated the same as peptide pulsed. For peptide on-rates, T2s were 228 
treated as before but for the durations specified in the results (1-3h) then stained and fixed. For 229 
peptide off-rates T2s were pulsed overnight, then a proportion of them stained immediately and fixed 230 
as above, with remaining cells being washed in an excess of media (2 times using 4 mls) and 231 
incubated in 4.5 ml of AIM-V for the specified times (h) at 37°C and 5% CO2, to allow peptide to 232 
dissociate, then stained and fixed as before. Flow cytometry was performed on a FACSCanto II (BD 233 
Biosciences) and data analysed with FlowJo software (TreeStar). 234 
 235 
2.12 Peptides used in this study 236 
This study made use of the HIV SL9 peptide and variants thereof. The sequences and origin of these 237 
peptides, and other control peptides utilized, are listed in Table 1. 238 
 239 
3. RESULTS 240 
3.1 868 TCR binding to A2-SLYNTVATL involves extensive structural re-organisation 241 
Previous studies have demonstrated that over 1.7% of CD8+ T-cells from HLA A2+ HIV infected 242 
patient 868, stained with A2-SLYNTVATL tetramer (10). 75% of these tetramer+ cells expressed a 243 
TRBV5-6+ TCR and an identical TRBV5-6 ß-chain was observed in 10/18 transcripts sequenced in 244 
this study (CDR3 sequence CASSLSAVQNNEQF) (10). This same ß-chain was later shown to be 245 
present in all A2-SLYNTVATL tetramer+ cells in a T-cell line grown from patient 868 in 1996 (9). 246 
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TCR chain antibody staining showed that all of these A2-SLYNTVATL tetramer+ T-cells co-253 
expressed a TRAV12-2 chain (11). Our previous study confirmed that CD8+ T-cells expressing this 254 
TCR were unable to control HIV virus in vitro (11). Nevertheless, we were able to use phage display 255 
to select an artificially enhanced version of the 868 TCR that could recognise the SLFNTIAVL 256 
ultimate escape variant; thereby engineering foresight into an immune receptor (11). The detection of 257 
common SL9 escape mutants on the surface of HIV-infected HLA A2+ cells by CD8+ T-cells 258 
expressing engineered, but not wildtype, 868 TCR reinforced earlier studies suggesting that these 259 
mutants are presented by HLA A2 and that escape from the wildtype epitope is mediated by loss of 260 
TCR binding (so-called ‘TCR escape’) (6, 7, 11, 18). To understand how positions 3, 6 and 8 in SL9 261 
impinge on TCR binding, we solved the structure of the wildtype 868 TCR in complex with A2-262 
SLYNTVATL to 2.9Å resolution (Table 2). The 868 TCR bound to A2-SLYNTVATL with a 263 
conventional, centrally-located, diagonal orientation with the TCR α-chain positioned over the α2 264 
helix of MHC class I and the TCR β-chain positioned over the α1 helix (Fig 1A). The TCR crossing 265 
angle of 51.6° lies within the normal range for human TCR-pMHC complexes (28), enabling 266 
positioning of the TCR CDR3 loops centrally over the peptide, and the CDR1 and CDR2 loops 267 
predominantly over the MHC helices (Fig 1B). To gain extra insight into the mechanism by which 268 
the 868 TCR adopted this binding mode, we also solved the structure of the unbound 868 TCR 269 
(Table 2). Comparison with the 868-A2-SLYNTVATL complex structure showed that extensive 270 
structural reorganisation of the CDR3 loops was required to avoid clashes with the solvent exposed 271 
residues in the SL9 peptide. This resulted in an induced fit, or conformational pre-equilibrium 272 
binding mode where the TCR exists in two conformations in the unbound state, with the CDR3a 273 
loop ‘moving’ 6.9Å and the CDR3b moving 3.2Å between the bound and unbound TCR structures 274 
(Fig 1C).  275 
Closer examination of the interface between the TCR and the pMHC showed that the CDR3 loops 276 
almost exclusively made contacts with the peptide, forming a pincer around the solvent exposed 4N 277 
and 5T residues in the peptide (Fig 2A&B). The TCR-peptide interaction included 10 hydrogen 278 
bonds and 52 vdW contacts, mainly focused on 4N. The CDR1 and CDR2 loops primarily contacted 279 
the α helices of the MHC, including interactions with all three restriction triad residues (MHC 280 
residues 65R, 69A and 155Q) as well as strong interactions with MHC residues 72Q and 154E (Fig 281 
2C&D). Although most of the TCR-pMHC interactions were focused on these two peptide residues 282 
and five MHC residues, the 868 TCR bound with a broad footprint, making additional bonds with all 283 
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but two peptide residues (1S and 9L) and a further 14 MHC residues. In total, the 868 TCR made 20 286 
hydrogen bonds, and 121 van der Waals (vdWs) contacts with A2-SLYNTVATL (Table 3), which is 287 
in the higher range compared to previously published viral TCR-pMHC complexes (29). In 288 
summary, the 868 TCR utilized an induced fit, or conformation selection, binding mode to form a 289 
pincer-like interaction around the central solvent-exposed portion of the peptide. Additional contacts 290 
with distal peptide residues enabled a relatively extensive and broad binding interface between the 291 
TCR and pMHC. 292 
3.2 TCR structure with the ultimate SL9 escape variant 293 
The 868-A2-SLYNTVATL complex structure demonstrated that the dominant contacts with the SL9 294 
peptide were with the 4N residue rather than with the 3Y, 6V or 8T residues that result in immune 295 
escape when substituted to create the SLFNTIAVL ultimate escape variant (6, 7). Alanine scan 296 
mutation across the SL9 peptide backbone showed an almost complete loss of recognition with the 297 
L2A and Y3A changes. Alanine substitution at positions 4, 5 and 6 had the next greatest effect 298 
whereas peptides substituted at positions 1, 8 and 9 exhibited recognition equivalent to the wild type 299 
peptide (Fig 2E). In order to gain insight as to how natural escape mutations impinge on TCR 300 
binding, we also solved the structure of the 868 TCR with the SLYNTIATL variant present in the 301 
patient at the time the blood sample was used to grow the 868 T-cell clone (9), and the SLFNTIAVL 302 
ultimate escape variant (Table 2). Comparison of these structures with the 868 TCR in complex with 303 
the A2-SLYNTVATL index sequence showed that the 868 TCR engaged all the antigens in a similar 304 
conformation and crossing angle (Fig 3A&B). We were initially surprised at being able to solve the 305 
structure of the 868 TCR in complex with the SLFNTIAVL peptide as this triple mutant is known to 306 
escape from CD8+ T-cells (6, 7). Indeed, this mutation is not well recognized by T-cells bearing the 307 
868 TCR (9, 11). The failure of CD8+ T-cells to recognize the SLFNTIAVL mutation has previously 308 
been attributed to reduced interactions with the TCR (6, 7, 18, 23). Earlier structural analyses of A2-309 
SLYNTVATL and A2-SLFNTIAVL have concluded that all three substitutions directly affected 310 
TCR recognition (6, 7).  However, we observed only minor differences at the TCR-peptide interface 311 
with these two ligands. For example, the 868 TCR made 3 hydrogen bonds and 12 vdWs with 312 
peptide residues 3Y, 6V and 8T in the SLYNTVATL peptide compared to 2 hydrogen bonds and 15 313 
vdWs contacts with 3F, 6I and 8V in the SLFNTIAVL peptide (Fig 3C&E). The total number of 314 
contacts in each complex (868-A2-SLYNTVATL: 141, 868-A2-SLFNTIAVL: 146) was also similar, 315 
demonstrating that the 868 TCR could tolerate mutations at residues 3, 6 and 8 in SL9 (Table 3). 316 
Deleted: 2317 
Deleted: 1318 
Deleted: 2319 
I rev
Escape from immunodominant HLA A2-restricted HIV epitope 
 
 
11 
Deleted:   Running Title
Thus, because our structural data were inconsistent with the hypothesis that SLFNTIAVL primarily 320 
affects TCR binding, and because sum contact numbers do not necessarily represent the accurate 321 
binding energy between two molecules, we undertook further structural and biophysical 322 
experimentation to determine the mechanism that results in poor T-cell recognition of SLFNTIAVL.  323 
3.3 A2-SLYNTVATL does not alter conformation when bound to 868 TCR 324 
Previous studies comparing SLYNTVATL and the SLFNTVATL mutated peptide showed that they 325 
adopted different conformations within the HLA A2 binding groove (7, 22). The T-cell recognition 326 
and on-rate kinetics with the G10 SL9-specific TCR in this study were very similar with A2-327 
SLYNTVATL and A2-SLFNTVATL, leading the authors to conclude that one conformation, 328 
common to both peptides, was recognised by TCRs (22) and suggesting that TCR interactions with 329 
either A2-SLYNTVATL or A2-SLFNTVATL required an induced fit in the pMHC. Thus, SL9 330 
derived peptides may bind to MHC dynamically and undergo conformational changes during TCR 331 
docking. Conformational peptide changes would likely elicit an entropic penalty during TCR 332 
ligation, not revealed by differences in contacts, and could contribute to weaker binding. However, 333 
based on previously solved structures (A2-SLYNTVATL (22), A2-SLFNTVATL (22) A2-334 
SLANTVATL (21), A2-SLYNTIATL (21), A2-SLYLTVATL (21), A2-SLYNVVATL (21), A2-335 
ALYNTAAAL (21) and A2-SLFNTIAVL (21)), some of which we replicated in this study, we show 336 
that A2-SLYNTVATL, A2-SLYNTIATL and A2-SLFNTIAVL all adopt a similar structure to every 337 
unbound SL9 peptide variant, apart from A2-SLFNTVATL (22), when ligated to the 868 TCR (Fig 338 
4). These data make it possible to be more definitive about the direction of travel of the previously 339 
suggested induced fit model (22) (i.e. the odd one out is A2-SLFNTVATL and this peptide 340 
presumably adopts the more conventional structure for A2-SLYNTVATL type ligands prior to, or at 341 
the time of, TCR binding). Furthermore, these data do not support the notion that HIV escape is 342 
mediated by dynamic differences in ligand engagement during TCR binding to SL9 variants. 343 
3.4 The 868 TCR adopts a similar energetic strategy during binding to SL9 escape variants 344 
We next explored the evidence for HIV escape being mediated by distinct TCR binding parameters. 345 
It has been previously shown that the G10 SL9-specific TCR binds with a similar affinity to both A2-346 
SLYNTVATL (KD = 2.2 µM) and A2-SLFNTVATL (KD = 5.2 µM) by surface plasmon resonance 347 
(SPR) (22). Another study demonstrated that half maximal pMHC tetramer binding (DR50) to the 348 
SL9-specific D3 TCR was near identical for A2-SLYNTVATL, A2-SLFNTVATL, A2-349 
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SLYNTVAVL, A2-SLFNTVAVL and A2-SLFNTIAVL (21). Finally, we have previously shown 352 
that the 868 TCR binds to a range of SL9 variants (11) (A2-SLYNTVATL, A2-SLYNTIATL, A2-353 
SLYNTIAVL, A2-SLYNTVAVL, A2-SLFNTIATL, A2-SLFNTVAVL and A2- A2-SLFNTVATL, 354 
A2-SLFNTIAVL). Consequently, the available data shows that SL9-specific TCRs can engage SL9 355 
variants within an affinity range that would be expected to easily activate T-cells. Here, we 356 
reproduced SPR binding assays with the 868 TCR for the three ligands included in this study. These 357 
data demonstrated that the 868 TCR bound to A2-SLYNTVATL with a KD of 82 nM (Fig 5A) 358 
confirming that this is, by far, the strongest binding natural TCR-peptide-MHC interaction ever 359 
recorded (30, 31). Indeed, the affinity was even greater with the A2-SLYNTIATL variant (KD =38 360 
nM; Fig 5B) that dominated in the patient at the time the blood sample was taken that was used to 361 
generate the 868 T-cell line (9, 10). 868 TCR interactions with A2-SLYNTVATL and the A2-362 
SLYNTIATL variant were characterized by a relatively slow off-rate (koff = 1.6x10
-2 – 7.3x10-3 s-1) 363 
compared to the majority of other natural TCR-pMHC interactions (average koff ~2x10
-1 s-1) (30). 364 
Although the strength of the 868-A2-SLFNTIAVL interaction was 21-fold and 45-fold weaker than 365 
for A2-SLYNTVATL or A2-SLYNTIATL respectively, due to a much faster off-rate (koff = 2.1x10
-1 366 
s-1), the affinity (KD of 1.77 µM; Fig 5C) was still in the range of the very best natural anti-pathogen 367 
TCRs (31, 32). Thus, this weaker affinity alone was unlikely to explain the ability of the 368 
SLFNTIAVL variant to evade T-cell detection. Indeed, we have described a functional HLA A2-369 
restricted TCR that binds its cognate pMHC with over 100-fold weaker affinity than the 868 TCR 370 
and A2-SLFNTIAVL (33, 34). To get a more complete picture of how the 868 TCR engages its 371 
cognate ligands we also undertook thermodynamic analyses by SPR (Fig 5D-F, Table 4) and directly 372 
by isothermal calorimetry (ITC; Fig 5G-I). The results of these independent techniques correlated 373 
well and showed that 868 TCR engagement was driven by energetically favorable enthalpy and 374 
entropy changes to all three ligands. Thus, for the 868 TCR, there was a net increase in the number of 375 
electrostatic interactions and a transition from order-disorder during binding. Considering that the 376 
868 TCR CDR3 loops underwent similarly large conformational changes during engagement to all 377 
three SL9 variants studied here (shown for 868-A2-SLY interaction in Fig. 1C), a movement that 378 
would probably be entropically unfavorable, the expulsion of ordered water molecules from the 379 
interface, and/or order-disorder transitions in other parts of the molecules presumably contributed to 380 
the net favorable entropic change of the interaction. The lower affinity of 868 TCR for A2-381 
SLFNTIAVL compared to A2-SLYNTVATL or A2-SLYNTIATL was associated with a much 382 
reduced enthalpic component, but more favorable entropy. We used 2D binding analysis to confirm 383 
our observations using SPR (Fig 5J&K). In accordance with our previous findings with other TCRs 384 
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(34, 35), we observed an identical relationship between the strength of interaction between 868 and 390 
the three SL9-derived ligands by 2D analysis and SPR. 868-A2-SLYNTIATL was characterized by 391 
the strongest 2D effective affinity (1.6x10-3 µm4), followed by 868-A2-SLYNTVATL (1.0x10-3 392 
µm4), with 868-A2-SLFNTIAVL generating the weakest effective 2D affinity (5.9x10-4 µm4). To 393 
further confirm our observations from 2D and 3D binding experiments, we next examined the 394 
binding of pMHC tetramers to the 868 TCR at the T-cell surface. Staining of 868 TCR transduced 395 
CD8+ primary T-cells was similar for tetramers made with A2-SLYNTVATL, A2-SLYNTIATL and 396 
A2-SLFNTIAVL (Fig 6A). The CD8 coreceptor is known to bind to a site on MHC class I distinct 397 
from the TCR docking platform and cooperates with the TCR to aid the engagement of pMHC 398 
tetramers (36) and the absence of CD8 binding is known to raise the TCR affinity threshold required 399 
for tetramer staining (37, 38). 868 TCR+ Jurkat T-cells, that do not express CD8, also stained equally 400 
well with A2-SLYNTVATL, A2-SLYNTIATL and A2-SLFNTIAVL tetramers (Fig 6B). Given our 401 
observations that the TCR affinity threshold required for T-cell activation is considerably lower than 402 
that required for pMHC tetramer binding (37) and finding that these reagents can even fail to stain 403 
fully functional T-cells (39, 40), our results suggest that the SLFNTIAVL ultimate escape variant 404 
would still be a very efficient T-cell agonist. Indeed, the 868 TCR transduced primary CD8+ T-cells 405 
exhibited similar reactivity to SLYNTVATL and SLFNTIAVL peptides when using standard T-cell 406 
activation assay whereby T-cells, antigen-presenting cells and peptide are added directly to tissue 407 
culture wells and allowed to incubate (Fig 6C). We conclude that while there is a substantial 408 
reduction of TCR binding to the SLFNTIAVL triple mutant sequence, this reduction cannot explain 409 
the observed immune escape per se as assumed by all previous studies in this system (6, 7, 11, 23). 410 
The other way by which peptides can escape from host CTL surveillance is by mutating MHC 411 
anchors to reduce binding and presentation at the infected cell surface. However, previous studies 412 
have shown that the SLFNTIAVL peptide binds to HLA A2 with 50-400% of the affinity the index 413 
SL9 sequence depending on the study (Table 5). Such minor relative differences were not thought to 414 
be able to explain how the triple mutant peptide escapes from CTL (6, 7, 9, 18). Our own studies 415 
with a modified version of the 868 TCR that recognizes the escape variants well, showed that this 416 
TCR could recognize CD4+ T-cells infected with primary HIV isolates carrying known escape 417 
variants (11). Thus, these variants must be presented at the cell surface in the context of HLA A2. 418 
Importantly, these variants were not recognized by T-cells expressing the wildtype 868 TCR thus 419 
verifying that these viruses are indeed escape mutants (11). Consequently, the established literature 420 
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indicates that the common variant peptides in this system bind sufficiently well to HLA A2 to be 424 
presented (6, 7, 9, 18) and sufficiently well to the 868 and D3 TCRs to be recognized by T-cells 425 
expressing these SL9-specific receptors. These apparently incongruous findings prompted us to next 426 
re-examine peptide binding in the SL9 system. 427 
3.5 CTL escape by the ultimate SL9 escape variant mediated by a fast peptide off-rate 428 
Detailed analysis of the thermal melting of A2-SLYNTVATL, A2-SLYNTIATL and A2-429 
SLFNTIAVL by circular dichroism showed the melting temperature (Tm) of the wild-type peptide 430 
was higher than that of the triple mutant (57 ⁰C compared to 49 ⁰C; Fig 7A&B) suggesting that the 431 
triple mutant is less stable. These data are in accordance with two previous studies showing that 432 
SLFNTIAVL binds to HLA A2 with ~50% reduced affinity compared to SL9 (9, 18) but at odds 433 
with two studies indicating that SLFNTIAVL is the better ligand (6, 7). Peptide binding to HLA A2 434 
has not previously been thought to result in the immune escape observed with this epitope, which 435 
instead has been attributed to a lack of recognition by SL9-specific TCRs  (6, 7, 11, 23). Stabilization 436 
of HLA A2 at the T2 cell surface in the continuous presence of 100 µM peptide (steady state binding; 437 
Fig 7C) showed that the SLFNTIAVL peptide stabilized HLA A2 with 89% of that seen with the 438 
wildtype SL9 peptide after 3 h. This relatively minor difference increased in an overnight assay 439 
where stabilization with SLFNTIAVL was ~65% of that seen with the wildtype peptide. Our 440 
previous examinations of HLA A2 peptide stability by SPR have shown that good agonists produce 441 
pMHC with a half-life of >6 h in a cell free system (41). Similar experiments, performed by 442 
examining the relative binding of 868 TCR to A2-peptide by SPR over a time course at 37 °C, 443 
showed that both A2-SLYNTVATL and A2-SLYNTIATL had a half-life of >7 h. In contrast, the 444 
half-life of A2-SLFNTIAVL on the same chip was <2 h (Fig 8A). We thus reasoned that the 445 
stabilization of peptide-HLA measured in a short-term binding assay like those previously used in 446 
this system (9, 18) would be determined more by peptide on-rate than the peptide off-rate or dwell 447 
time. To further test this possibility, we examined the ‘on rate’ of peptide in T2 cell stabilization 448 
assays. Relative stabilization was similar for the SLYNTVATL, SLFNTIAVL and the GILGFVFTL 449 
influenza matrix-derived peptide that is often used as a positive control for HLA A2 binding (Fig 8B 450 
left panel). We also examined the stability of these A2-peptide complexes at the cell surface by 451 
monitoring the amount of HLA A2 on T2 cells incubated with each peptide prior to washing and 452 
further culture. The vast majority of HLA A2 stabilized with GILGFVFTL or SLYNTVATL peptide 453 
was still present at the cell surface 3 h after the peptide was removed from the assay by cell washing. 454 
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In stark contrast, most of the HLA A2 stabilized by the SLFNTIAVL peptide had decayed in half 459 
this time (Fig 8B right panel). Collectively, these binding data explain how previous studies, using 460 
short-term binding assays in the continuous presence of peptide, have shown minor differences in the 461 
binding of SL9 and SLFNTIAVL escape variant (Table 5). They also suggest that the dominant 462 
mechanism by which the SLFNTIAVL mutant allows immune escape is due to this peptide 463 
producing a much shorter-lived peptide-HLA complex.  This reduced half-life of antigen at the 464 
infected cell surface would be expected to considerably reduce the antigen density on infected cells 465 
and thereby facilitate immune escape. To test this notion, we next examined how long peptide pulsed 466 
cells could remain as T-cell targets for CD8+ T-cells transduced with the wildtype 868 TCR. These 467 
revealing experiments allowed examination of the combined effects of differences in TCR binding 468 
and HLA stability in a relevant biological context. Cells pulsed with the SLYNTVATL remained 469 
effective targets for 868 TCR-expressing CD8+ T-cells after 24 h of culture (Fig 8C; Supp Fig 1). In 470 
contrast, targets pulsed with the SLFNTVATL, SLYNTIATL or SLYNTVAVL variant peptides 471 
showed reduced levels of recognition after 24 h. The SLFNTIAVL triple mutant sequence produced 472 
the largest effect and was recognized well if experiments were performed immediately but 473 
recognition dropped to less than 20% of that seen for the SLYNTVATL peptide at t0, after targets 474 
were cultured for 24 h prior to the T-cell recognition assay. Similar data were observed when primary 475 
CD4+ T-cells, which form the major reservoir for HIV virus in vivo, were used as targets (Fig 8D). 476 
Relative to SLYNTVATL, the SLFNTIAVL pulsed cells made better target at t0 (125%) but their 477 
ability to activate the 868 TCR cells diminished to 18% when allowed to culture for 24 h prior to 478 
assay (Fig 8D; (Supp Fig 2). These results suggest that the major mechanism by which 479 
SLFNTIAVL escapes from CTL is through loss of peptide-HLA stability, although reduced TCR 480 
interaction with this mutant is also likely to play a secondary role.  481 
4. DISCUSSION 482 
Recognition and escape from the HLA A2-restricted HIV epitope SL9 has been examined in well 483 
over 50 studies to date but major questions are still outstanding in this system as there has been no 484 
TCR-A2-SL9 co-complex structure. Here we solved the structure of the free 868 TCR, a TCR first 485 
described almost 20 years ago (10), and the structure of this TCR in complex with A2-486 
SLYNTVATL. Comparison of the free and ligated TCR structures suggested an 'induced fit' 487 
mechanism that involved major structural reorganization of the antigen binding face of the TCR. The 488 
CDR3 loops made the biggest movement (almost 7Å for CDR3a and >3Å for CDR3b) to avoid 489 
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steric clashes with the central portion of the peptide, whilst the CDR1 and CDR2 loops interacted 497 
mainly with MHC via a more ‘lock-and-key’ interaction.  498 
It has been known for over a decade that that the SLYNTVATL and SLFNTVATL bind to HLA A2 499 
with very different conformations, but engage the G10 TCR with near identical on-rates, leading the 500 
authors to conclude that one conformation, common to both peptides, was recognized by TCRs (22). 501 
Since A2-SLYNTVATL does not change upon TCR binding, we can now be confident that the 502 
conformation adopted by this, and many other SL9 variants (21), dominates during TCR recognition. 503 
Thus, the evidence suggests that A2-SLFNTVATL undergoes an induced fit upon TCR binding (22) 504 
although conclusive proof will await a TCR-A2-SLFNTVATL structure. We further solved the co-505 
complex structure of the 868 TCR with the A2-SLYNTIATL (the variant that predominated in 506 
patient 868 in 1996 when the patient blood sample from which this T-cell clone was grown was 507 
taken), and the structure of the 868 TCR in complex with the A2-SLFNTIAVL, the ultimate escape 508 
variant in this system. Resolution of the latter structure came as a surprise as residues that mutate in 509 
positions 3, 6 and 8 to produce this mutant are known to be solvent exposed and had been assumed to 510 
act as prominent TCR contacts (6, 7, 21-23). In contrast to this prevailing hypothesis we found that 511 
the asparagine at position 4 was the dominant contact residue. Indeed, there were more contacts with 512 
this residue than with the position 3 tyrosine, position 6 valine and position 8 threonine combined. 513 
An alanine mutation scan across the peptide backbone showed that while positions 4 and 5 in 514 
SLYNTVATL were important for recognition, the most severe non-MHC anchor change was Y3A. 515 
In accordance, the position 3Y sub-library also gave the strongest response of the 180 sub-libraries 516 
during a 9-mer positional scanning combinatorial library (PS-CPL) screen of T-cells transduced with 517 
the 868 TCR (42).  The importance of the tyrosine residue at position 3 is consistent with our 518 
previous observation that large bulky amino acids at this position in HLA A2-bound peptides can 519 
form a bridge with more C-terminal residues (usually position 5) (43). Replacing residue 3 with a 520 
smaller alanine side chain can abolish this important intra-peptide stabilization and have knock-on 521 
effects at peptide residue 4 that abrogate TCR binding. Thus, our findings here point towards a 522 
common mechanism of peptide presentation by HLA A2 in which peptide residue 3 can be essential 523 
for maintaining antigenic identity. 524 
We next undertook a detailed biophysical and thermodynamic study of 868 TCR binding to A2-525 
SLYNTVATL, A2-SLYNTIATL and A2-SLFNTIAVL. The 868 TCR exhibited, by far, the 526 
strongest affinity of a peptide-HLA ligand for a natural TCR (31) and bound to A2-SLYNTVATL 527 
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and A2-SLYNTIATL ligands with KDs of 82 nM  and 38 nM respectively, or over 10X stronger 528 
binding than the next highest TCR-pMHC interaction measured by BIAcore (31). The median 529 
affinity for human anti-viral TCR-pMHC interactions is KD ~5 µM (31). 868 TCR binding was 530 
characterized by a relatively slow off-rate from the A2-SLYNTVATL and A2-SLYNTIATL ligands. 531 
The other SL9-TCR that has been examined by SPR, G10, had an off-rate 3.75 times faster than 868, 532 
and a 4.5 times slower on rate, resulting in a weaker affinity of KD of 2.2 µM for A2-SLYNTVATL 533 
compared to 868 (22). While binding of the 868 TCR was much reduced for A2-SLFNTIAVL 534 
compared to the other ligands, it still had a very respectable affinity (KD=1.77 µM) that falls at the 535 
higher end of the spectrum for TCR agonists (31).  536 
The mode of 868 TCR engagement and its affinity with the A2-SLFNTIAVL ultimate escape variant 537 
in this system did not lend full support to the prevailing belief that loss of recognition of SL9 occurs 538 
mainly via interfering with TCR binding. The fact that CD8+ T-cells transduced with the 868 TCR 539 
could recognize SLFNTIAVL pulsed target cells well and stained with A2-SLFNTIAVL tetramers 540 
was also a surprise, but in accordance with an earlier study that showed that A2-SLFNTIAVL bound 541 
to the D3 TCR as well as A2-SLYNTVATL in tetrameric form and that the SLFNTIAVL 542 
concentration required for half maximal lysis was a highly respectable 4 x10-10 M (21). In further 543 
accordance with positions 3, 6 and 8 not dominating A2-SL9-specific TCR binding, the position 4 544 
asparagine sub-library was by far the most potent of the 180 sub-mixtures for activating T-cell clone 545 
003 known to express a different SL9-specific TCR (42). These combined data do not support the 546 
notion that the SLFNTIAVL escapes from CTL via lack of TCR binding, prompting us to take a 547 
closer look at the MHC binding of ligands in this system. Data from three different studies using 548 
three different methodologies show that SLFNTIAVL binds to HLA A2 with 50-400% of the affinity 549 
of SLYNTVATL. Our previous SPR experiments have shown that good agonists produce pMHC 550 
with a half-life of >6 h in a cell free system (41). Indeed, our data here show that both A2-551 
SLYNTVATL and A2-SLYNTIATL had half-lives of over 7 h on an SPR chip maintained at 37 °C 552 
compared to <2 h for A2-SLFNTIAVL. We reasoned that the peptide binding assays that have been 553 
performed previously in this system, including by ourselves (9), would be most influenced by peptide 554 
on-rate but that the biology would be most linked to peptide off-rate at the target cell surface. HLA 555 
A2+ target cells pulsed with SLYNTVATL peptide remained effective targets for SL9-specific CD8+ 556 
T-cells after 24 h of culture as has been observed with a different HIV Gag-derived epitope (27). The 557 
SLFNTVATL, SLYNTIATL and SLYNTVAVL peptides (which bind to the 868 TCR with 558 
I r vi
ew
Escape from immunodominant HLA A2-restricted HIV epitope 
 
18 
This is a provisional file, not the final typeset article 
dissociation constants of 2.9 µM, <100 nM and ~300 nM respectively (31)) were seen well when 559 
targets presenting these ligands were used immediately for T-cell assays but exhibited only 67%, 560 
60% and 35% recognition of that observed with SLYNTVATL peptide when targets were cultured 561 
for 24 h prior to the T-cell assay. The biggest effect was observed with the SLFNTIAVL where 562 
>80% of the activity was lost after 24 h of culture. These results were supported by other experiments 563 
looking the stability of the A2-SLFNTIAVL complex in comparison to other ligands.  564 
Collectively, our results suggest that the instability of the A2-SLFNTIAVL molecule is likely to 565 
provide the major mechanism of escape from SL9-specific CTL. The accumulation of mutations at 566 
positions 3, 6 and 8 to fixation over a 10-year period (6, 7) demonstrates the extraordinary lengths 567 
that HIV will go to in order to avoid detection by these key antiviral cells. Our study further 568 
highlights that the results of short-term, steady state peptide binding assays can be misleading and 569 
suggests that future studies should employ more relevant biological readouts. 570 
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10. FIGURE LEGENDS 778 
Figure 1. Structural analysis of the 868-A2-SL9 binding mode. A. The overall binding mode of 779 
the 868 TCR (red and magenta cartoon) interacting with HLA A2 (grey cartoon) and the 780 
SLYNTVATL peptide (red sticks and surface). B. Surface representation of the A2-SLYNTVATL 781 
complex looking down at the peptide. Positions of the 868 TCR CDR loops (1α - red, 2α - green, 3α - 782 
blue, 1β - yellow, 2β - cyan, 3β - orange) and the crossing angle of the TCR with the MHC groove is 783 
shown. C. The positions of the 868 TCR CDR3 loops differ considerably between the ligated (red 784 
cartoon) and unligated (grey cartoon) structures. 785 
Figure 2. The 868 TCR focusses on residues 4N and 5T in the peptide. Hydrogen bonds show as 786 
red dotted lines, van der Waal’s contacts shown as black dotted lines in panels A-D. A. The 868 TCR 787 
(CDR3α in blue, CDR1α red and CDR3β orange sticks) binding to the solvent exposed peptide 788 
residues 4N and 5T in the peptide (red sticks). B. The 868 TCR (CDR3α in blue, CDR1α red sticks 789 
and surface) forms a tight pocket around peptide residue 4N (red sticks) during binding. C&D. The 790 
restriction triad residues 72Q, 69A and 155Q (grey sticks) play a central role in 868 TCR-MHC 791 
mediated interactions (TCR CDR3α residues shown in blue, CDR2β in cyan and CDR1α in green 792 
sticks). E. 868 TCR transduced CD8+ T-cells from two HLA A2+ donors were co-incubated with T2 793 
cells and alanine substituted peptides of SLYNTVATL (alanine already at position 7) overnight and 794 
supernatants used for MIP-1β ELISA. Nonlinear regression curves and pEC50 for each peptide are 795 
displayed. 796 
Figure 3. The 868 TCR uses a virtually identical conformation when interacting with the 797 
common escape mutants SLYNTIATL and SLFNTIAVL. A. Identical overall binding mode of 798 
868 TCR interacting with A2-SLYNTVATL (red), A2-SLYNTIATL (orange) and A2-SLFNTIAVL 799 
(green). HLA A2 in grey cartoon. B. Surface representation of the A2-SLYNTVATL complex 800 
looking down at the peptide. Positions of the 868 TCR CDR loops in the A2-SLYNTVATL (red), 801 
A2-SLYNTIATL (orange) and A2-SLFNTIAVL (green) complexes. Crossing angle of the TCR is 802 
indicated. C. Contacts between the 868 TCR and residues 3Y, 6V and 8T in the SLYNTVATL 803 
peptide that constitute the positions that a commonly mutated by HIV. D. Contacts between the 868 804 
TCR and residues 3Y, 6I and 8T in the SLYNTIATL peptide. Although slightly different, the total 805 
number of contacts between the 868 TCR and A2-SLYNTIATL is similar to the 868-A2-806 
SLYNTVATL complex. E. Contacts between the 868 TCR and residues 3F, 6I and 8V in the A2-807 
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SLFNTIAVL triple escape mutant peptide. Again, the total number of contacts between the 868 TCR 808 
and A2-SLFNTIAVL is similar to the complex with the wildtype index peptide. Hydrogen bonds 809 
show as red dotted lines, van der Waal’s contacts shown as black dotted lines in panels C-E. 810 
Figure 4. 868 TCR binding alters the peptide conformation of the A2-SLYNTVATL escape 811 
mutants. Structural comparison of the A2-SLYNTVATL escape variants unligated and in complex 812 
with the 868 TCR. A&B. A2-SLYNTVATL in complex with the 868 TCR (red sticks) vs unligated 813 
A2-SLYNTVATL (cyan sticks). Small changes in the positions of the side chains that occur during 814 
TCR binding are circled. C&D. A2-SLYNTIATL (orange sticks) in complex with the 868 TCR vs 815 
unligated A2-SLYNTIATL (yellow sticks). Small changes in the positions of the side chains that 816 
occur during TCR binding are circled. E&F. A2-SLFNTIAVL (green sticks) in complex with the 817 
868 TCR vs unligated A2-SLFNTIAVL (purple sticks). Small changes in the positions of the side 818 
chains that occur during TCR binding are circled. 819 
Figure 5. Binding affinity and thermodynamic analysis of the 868 TCR binding to A2-820 
SLYNTVATL, A2-SLYNTIATL and A2-SLFNTIAVL. A-C. Binding and kinetic analysis of the 821 
868 TCR interaction with A. A2-SLYNTVATL, B. A2-SLYNTIATL and C. A2-SLFNTIAVL. 822 
Experiments were performed independently using a BIAcore T100 equipped with a CM5 sensor chip 823 
and repeated in triplicate on different days using different protein preparations. Representative data 824 
are shown. D-F. Thermodynamic analysis of 868 TCR with the aforementioned ligands. SPR as 825 
above. Thermodynamic parameters were calculated according to the Gibbs-Helmholtz equation (ΔG° 826 
= ΔH − TΔS°). The binding free energies, ΔG° (ΔG° = RTlnKD), were plotted against temperature 827 
(K) using non-linear regression to fit the three-parameters Van’t Hoff equation, (RT ln KD = ΔH° –828 
TΔS° + ΔCp°(T-T0) – TΔCp° ln (T/T0) with T0=298 K). G-I. Thermodynamic analysis of the 868 829 
TCR-pMHC interaction was also performed using isothermal titration calorimetry 200 instrument to 830 
directly measure ΔH. These analyses show consistent values to those generated by SPR. Overall, the 831 
868 TCR uses a generally similar binding mechanism and thermodynamic signature to interact with 832 
all three ligands. J. Effective 2D binding frequency, using at least 5 cell pairs, and calculated as an 833 
average of 100 cell-cell contacts. K. Effective 2D affinity (AcKa) calculated using adhesion 834 
frequency assays. 835 
Figure 6. 868 TCR-expressing T-cells bind escape mutant tetramers efficiently without the need 836 
for CD8. A. Primary CD8+ T-cells were co-transduced with the 868 TCR and rat (r)CD2 prior to 837 
staining with 0.5 µg (with respect to MHC) of irrelevant (A2-ALWGPDPAAA), A2-SLYNTVATL, 838 Deleted: SLY WT839 
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A2-SLYNTIATL and A2-SLFNTIAVL PE conjugated peptide-MHC tetramers. Cells are gated on 840 
rCD2+CD8+ cells. Histograms show staining with indicated PE-conjugated tetramer with the MFI of 841 
this population displayed. B. As for A, but 868 TCR and rat (r) CD2 were transduced into TCRβ 842 
chain negative Jurkat cells. MFI of tetramer staining is shown for cells in the rCD2+ tet+ gate. C. 868 843 
TCR transduced were incubated with T2 cells and either SLYNTVATL or SLFNTIAVL peptide at 844 
the concentrations shown for 5 h followed by the detection of CD107a and TNFα by flow cytometry.  845 
Figure 7. Stability of A2-SLYNTVATL, A2-SLYNTIATL and A2-SLFNTIAVL. A. CD thermal 846 
denaturation curves recorded at 218nm are shown for selected samples as indicated. Dots represent 847 
measured values fitted assuming a 2-state trimer-to-monomer transition (solid lines) as described in 848 
Materials and Methods. B. Bar graphs of the thermal stability with respect to melting temperature 849 
(upper) and van't Hoff's enthalpy of unfolding (lower panel). Error bars in A & B represent S.D. 850 
resulting from the multivariable curve fitting of data from one experiment with each peptide. C. T2s 851 
incubated for 3h or 22h with 10-5 M of each peptide (Influenza (Flu) Matrix, GILGFVFTL, HIV Gag 852 
wild-type SLYNTVATL and Gag triple mutant SLFNTIAVL) or DMSO control were stained for 853 
HLA-A2 and fixed. The dashed line is set at the mean fluorescence intensity (MFI) of the negative 854 
control peptide (EBV HPVGEADYFEY that binds HLA B*3501).  855 
Figure 8 Instability at the cell surface mediates viral escape by the triple mutant epitope, A2-856 
SLFNTIAVL A. Relative binding of 868 TCR to A2-peptide complexes by SPR over time. The SPR 857 
chip was maintained at 25°C. Functional half-life was determined by injecting the 868 TCR at a fixed 858 
concentration of 100 µM over 720 mins and recording the drop in total RUs over 8 different time 859 
points. A faster drop in RUs (converted into a T1/2) was interpreted to indicate greater peptide 860 
instability, detected by loss of binding by and antigen specific 868 TCR. B. Left panel shows relative 861 
HLA-A2 expression following incubation (0 h, 3 h and 22 h) of T2s with indicated peptide. Results 862 
are normalized to the maximum MFI seen for each peptide. The right panel shows T2 cells incubated 863 
with peptide for 22h prior to being washed and cultured in an excess of AIM-V media for the 864 
indicated times prior to staining and fixing. Data displayed as HLA-A2 expression relative to 865 
maximum seen at 22h. C. T2 cells were pulsed for 1 h with the peptides shown, washed extensively 866 
and then cultured in an excess of media for 3 h (black bar) or 24 h (open bar) before being co-867 
incubated for 5 h with T-cells from two donors transduced with the 868 TCR. CD107a and TNFα 868 
were used to establish percentage reactivity by flow cytometry. Values were normalized relative to 869 
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WT SLYNTVATL peptide. Standard error of the mean is shown for two different donor T-cells. 883 
Untransduced CD8+ T-cells did not respond to peptide (data not shown). Raw data for C is shown in 884 
Supplementary Fig 1. D. As C but using primary HLA-A2- and HLA-A2+ CD4+ T-cells as targets 885 
and culturing in excess media for either 0 h or 24 h prior to assay. Raw data for D is shown in 886 
Supplementary Fig 2.  887 
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11. TABLES 890 
Table 1.  891 
Peptides used in this study 892 
 893 
Peptide Sequence Abbreviation HLA-restriction Parent Protein 
SLYNTVATL SL9 HLA A*0201 HIV p17 Gag 
SLFNTVATL 3F HLA A*0201 HIV p17 Gag 
SLYNIVATL 6I HLA A*0201 HIV p17 Gag 
SLYNTVAVL 8V HLA A*0201 HIV p17 Gag 
SLFNIVAVL 3F6I8V HLA A*0201 HIV p17 Gag 
GILGFVFTL A2-flu HLA A*0201 Influenza Matrix 
HPVGEADYFEY  HLA B*3501 EBV EBNA-1 
  894 
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 897 
Table 2 898 
Data collection and refinement statistics for unligated 868 TCR and complex structures  899 
 868 TCR 868-A2-
SLYNTVATL 
868-A2- 
SLYNTIATL 
868-A2- 
SLFNTIAVL 
A2- 
SLYNTIATL 
A2- 
SLFNTIAVL 
Data collection       
Space group P 1 21 1 P 21 21 2 P 21 21 2 P 21 21 2 P 1 21 1 P 1 21 1 
Cell dimensions       
    a, b, c (Å) 87.5, 50.6, 
114.3 
211.1, 85.1,  
113.2 
207.6,84.7, 
112.1 
209.36, 85.11,  
113.15 
56.1, 80.1,  
57.6 
55.84, 79.03, 
58.37 
    a, b, g  (°)  90, 90.2, 90 90, 90, 90 90, 90, 90 90, 90, 90 90, 115.8, 90 90, 116.11, 90 
Resolution (Å) 43.8-2.1 
(2.13-2.07) 
64.8-2.9 
(3.01-2.94) 
34.0-2.9 
(2.96-2.89) 
99.5-2.8 
(2.82-2.75) 
31.7-1.6 
(1.59-1.55) 
48.4-1.7 
(1.70-1.66) 
Beam Line I24 I03 I03 I04-1 I03 I24 
Beam time code 6232-9 4532-1 6232-1 6232-10 4532-1 3262-9 
Rmerge (%) 5.0 (72.3) 12.5(95.9) 15.1(84.0) 11.7(86.7) 6.6 (73.3) 7.4 (130.3) 
I / sI 12.1(2.3) 12.4(2.1) 10.9(2.9) 13.0(2.5) 12.2(2.4) 9.5(2.1) 
Completeness (%) 98.6(99.6) 99.1(99.8) 100(100) 99.9(100) 99.4(97.7) 98.9(99.8) 
Redundancy 3.5(3.8) 7.5(7.1) 7.9(8.2) 7.4(7.6) 4.1(4.0) 3.6(3.7) 
No. reflections 60,507 
(4,492) 
44,013 
(3,213) 
45,223  
(3,284) 
53,560  
(3,895) 
66,024 
(4,752) 
 
53,691 
(4,000) 
       
Refinement       
No Rfree reflections  3,051 2,212 2,223 2,717 3,346 2,724 
Rwork / Rfree 18.9/22.3 19.4/28.9 18.8/27.5 19.2/27.0 14.4/19.4 17.5/20.8 
R.m.s. deviations       
Bond lengths (Å) 0.0189 0.015 0.012 0.017 0.025 0.017 
Bond Angles (°) 1.970 1.665 1.483 1.954 2.107 1.832 
Mean B value (Å2) 57.0 69.0 53.7 31.2 16.8 24.3 
Wilson B-fac (Å2) 40.7 72.2 60.3 58.9 17.2 22.5 
ML estimated 
coordinate error 
(Å) 
0.144 0.387 0.365 0.300 0.049 0.070 
* One crystal was used for solving each structure. 900 
Figures in brackets refer to the highest resolution bin.   901 
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Table 3.  902 
Summary of co-complex structures of 868-A2-SLYNTVATL, 868-A2-SLYNTIATL and 868-903 
A2-SLFNTIAVL 904 
 868-A2-
SLYNTVATL 
868-A2-
SLYNTIATL 
868-A2- 
SLFNTIAVL 
H-bonds (≤3.4Å) 20 20 18 
vdWs (≤4Å) 121 118 128 
Total contacts 141 138 146 
CDR1/CDR2/CDR3 
contacts (≤4Å): 
   
α chain 13/33/41 9/23/46 8/22/47 
β chain 0/17/37 0/27/43 0/24/45 
Peptide contacts 62 56 63 
MHC contacts 79 82 83 
Crossing Angle 51.6° 50.3° 51.7° 
Buried surface area (Å2) 2396.2 2469 2698 
Surface complementarity:    
TCR-MHC 0.50 0.51 0.55 
TCR-peptide 0.72 0.70 0.71 
TCR-pMHC 0.56 0.55 0.59 
HB = hydrogen bond, SB = salt bridge, WB = water bridge, vdWs = van der Waals interactions 905 
*A 3.4Å cut-off was used for HBs, SBs and WBs, and a 4Å cut-off was used for vdWs  906 
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Table 4.  908 
Affinity and kinetic measurements of 868-A2-SLYNTVATL, 868-A2-SLYNTIATL and 868-909 
A2-SLFNTIAVL at different temperatures 910 
MHC-Peptide Temp (°C) Kon (M
-1S-1) Koff (S
-1) KD
Kinj (µM) KD
Equi (µM) 
A2- 5 1.1x104 2.2x10-3 0.2 0.23 
SLYNTVATL 8 2.8x104 3.7x10-3 0.13 0.11 
 18 7.1x104 7.1x10-3 0.1 0.072 
 25 1.5x105 1.6x10-2 0.11 0.082 
 32 4.3x105 5.6x10-2 0.13 0.124 
 37 4.0x105 6.9x10-2 0.17 0.21 
A2- 5 9.2x103 1.3x10-3 0.13 0.16 
SLYNTIATL 8 5.4x104 2.7x10-3 0.05 0.048 
 18 7.6x104 4.2x10-3 0.055 0.035 
 25 1.4x105 7.3x10-3 0.052 0.038 
 32 3.1x105 1.9x10-2 0.06 0.049 
 37 6.4x105 3.2x10-2 0.05 0.11 
A2- 5 2.3x104 7.7x10-2 3.3 2.2 
SLFNTIAVL 8 6.3x104 1.1x10-1 1.7 1.7 
 18 1.3x105 1.8x10-1 1.42 1.65 
 25 1.4x105 2.1x10-1 1.48 1.77 
 32 1.6x105 3.0x10-1 1.9 2.11 
 37 1.0x106 5.3x10-1 0.53 2.3 
  911 
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Table 5.  913 
Relative binding of SLYNTVATL and SLFNTIAVL to HLA A2  914 
SLYNTVATL SLFNTIAVL METHOD 
100% 48% 
 
S35 methionine pulse chase 
(Eur J Immunol 1997, 27(9): 2323-2329) 
100% 
(KD = 50 nM) 
53% 
(KD = 94 nM) 
Direct competition with radio-labelled ligand 
(J Clin Invest 1998, 101(11): 2559-2566) 
100% 
(KD = 300 nM) 
300% 
(KD = 100 nM) 
HLA A2 ELISA 
(Nat Immunol 2006, 7(2): 179-189) 
 915 
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2.12 T-cell activation assays 
For peptide pulsing assays, T2 cells were incubated with peptide for 2h in 0.5 ml of AIM-V 
media followed by 4 washes with 4 ml of RPMI 1604 media. Post pulsing, T2 cells were 
incubated in 4.5 ml of AIM-V media at 37°C and 5% CO2 for 24h or used immediately (0 h), 
such that cells were ready at the same time. 868 TCR transduced and non-transduced T-cells 
(30,000) were rested overnight in R5 (as for R10 but with 5% FBS) then co-incubated in 96U 
well plates with T2s (60,000) in the presence of GolgiStop and GolgiPlug according the 
manufacturers (BD Biosciences, Oxford, UK), and anti-CD107a PE Antibody (H483, BD 
Biosciences). Controls included T-cells alone and T-cells with unpulsed T2s (negative 
control) or PHA. After 5h of incubation cells were labelled with the violet LIVE/DEAD 
fixable dead cell stain Vivid, anti-CD8 APC (BW135/80; Miltenyi Biotech) and anti-CD19 
pacific-blue (BioLegend) antibodies. Cells were then stained with anti-TNFα PE-Vio770 
antibody (CA2, Miltenyi Biotec) using a Cytofix/Cytoperm kit (BD Biosciences) according 
to manufacturer’s instructions. Flow cytometry was performed on a FACSCanto II (BD 
Biosciences) and data analysed with FlowJo software (TreeStar, Ashland, OR). For peptide 
alanine scans 868 TCR transduced T-cells were rested overnight in R5 then incubated with 
T2s (60,000) and peptides at specified concentrations for 18h in 96U well plates in 100 μl of 
R5. Supernatants (50 μl) were used for MIP-1β ELISA (R&D Systems, Minneapolis, 
Canada) and GraphPad Prism (GraphPad Software, Inc., La Jolla, CA) used to fit nonlinear 
regression curves and calculate EC50 for each peptide. 
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